New targeted therapies for thyroid cancer

Current Genomics

Volumn 12, Issue 8, 2011, Pages 626-631

  Antonelli, Alessandro ^a   Fallahi, Poupak ^a   Ferrari, Silvia M ^a   Ruffilli, Ilaria ^a   Santini, Francesca ^a   Minuto, Michele ^a   Galleri, David ^a   Miccoli, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anaplastic thyroid cancer; Aurora kinase inhibitors; BRAF; Peroxisome proliferator activated receptor ; RET; Targeted molecular therapies; Tyrosine kinase inhibitors; VEGFR

Indexed keywords

AXITINIB; B RAF KINASE; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CLM 29; CLM 3; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MOTESANIB; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THYROTROPIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; WITHAFERIN A; XL 184;

ANAPLASTIC THYROID CANCER; ANOREXIA; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CARDIOMYOPATHY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DEDIFFERENTIATED DIFFERENTIATED THRYROID CANCER; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SENSITIVITY; DRUG WITHDRAWAL; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOCYTOMA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN DISEASE; STROKE; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE;

EID: 82055208201     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920211798120808     Document Type: Article

References (54)

1. Deshpande, H.A.; Gettinger, S.; Sosa, J.A. Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. Core Evid., 2010, 4, 43-48.
2. Schlumberger, M.J. Papillary and follicular thyroid carcinoma. N. Engl. J. Med., 1998, 338, 297-306.
3. Castro, M.R.; Bergert, E.R.; Goellner, J.R.; Hay, I.D.; Morris, J.C. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J. Clin. Endocrinol. Metab., 2001, 86, 5627-5632.
4. Ward, L.S.; Santarosa, P.L.; Granja, F.; da Assumpção, L.V.; Savoldi, M.; Goldman G.H. Low espression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett., 2003, 200, 85-91.
5. Fagin, J.A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol., 2004, 183, 249-256.
6. Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer, 2005, 12, 245-262.
7. Sipple, J.H. The association of pheochromocytoma with carcinoma of thyroid gland. Am. J. Med., 1961, 31, 163-166.
8. Pasini, B.; Hofstra, R.M.; Yin, L.; Bocciardi, R.; Santamaria, G.; Grootscholten, P.M.; Ceccherini, I.; Patrone, G.; Priolo, M.; Buys, C.H. The physical map of the human RET proto-oncogene. Oncogene, 1995, 11, 1737-1743.
9. Anders, J.; Kjar, S.; Ibanez, C.F. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and calcium binding site. J. Biol. Chem., 2001, 276, 35808-35817.
10. de Groot, J.W.; Links, T.P.; Plukker, J.T.; Lips, C.J.; Hofstra, R.M. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr. Rev., 2006, 27, 535-560.
11. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J. Pediatric Gastroenterol. Nutr., 1982, 1, 603-607.
12. Gagel, R.F.; Levy, M.L.; Donovan, D.T.; Alford, B.R.; Wheeler, T.; Tschen, J.A. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann. Intern. Med., 1989, 111, 802-806.
13. Farndon, J.R.; Geraghty, J.M.; Dilley, W.G.; Handwerger, S.; Leight, G.S. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br. J. Surg., 1986, 73, 278-281.
14. Williams, E.D.; Pollock, D.J. Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen's disease. J. Pathol. Bacteriol., 1966, 91, 71-80.
15. Sippel, R.S.; Kunnimalaiyaan, M.; Chen, H. Current management of medullary thyroid cancer. Oncologist, 2008, 13, 539-547.
16. Wan, P.T.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R.; Cancer Genome Project. Mechanism of action of the RAF-ERK signaling pathways by oncogenic mutations of BRAF. Cell, 2004, 116, 855-867.
17. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard- Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.
18. Brummer, T.; Naegele, H.; Reth, M.; Misawa, Y. Identification of novel ERK-mediated feedback phosphorylation sites at the Cterminus of B-Raf. Oncogene, 2003, 22, 8823-8834.
19. Elisei, R.; Ugolini, C.; Viola, D.; Lupi, C.; Biagini, A.; Giannini, R.; Romei, C.; Miccoli, P.; Pinchera, A.; Basolo, F. BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow up study. J. Clin. Endocrinol. Metab., 2008, 93, 3943-3949.
20. Lee, X.; Gao, M.; Ji, Y.; Yu, Y.; Feng, Y.; Li, Y.; Zhang, Y.; Cheng, W.; Zhao, W. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann. Surg. Oncol., 2009, 16, 240-245.
21. Riesco-Eizaguirre, G.; Rodriguez, I.; de la Veja, A.; Costamagna, E.; Carrasco, N.; Nistal, M.; Santisteban, P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res., 2009, 69, 8317-8325.
22. Krause, D.S.; Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med., 2005, 353, 172-187.
23. Antonelli, A.; Fallahi, P.; Ferrari, S.M.; Carpi, A.; Berti, P.; Materazzi, G.; Minuto, M.; Guastalli, M.; Miccoli, P. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed. Pharmacother., 2008, 62, 559-563.
24. Fenton, C.L.; Lukes, Y.; Nicholson, D.; Dinauer, C.A.; Francis, G.L.; Tuttle, R.M. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J. Clin. Endocrinol. Metab., 2000, 85, 1170-1175.
25. Santoro, M.; Dathan, N.A.; Berlingieri, M.T.; Bongarzone, I.; Paulin, C.; Grieco, M.; Pierotti, M.A.; Vecchio, G.; Fusco, A. Molecular characteristics of RET/PTC3; a novel rearranged version of the RETproto-oncogene in human thyroid papillary carcinoma. Oncogene, 1994, 9, 509-516.
26. Saji, M.; Ringel, M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol. Cell Endocrinol., 2010, 321, 20-28.
27. Hou, P.; Ji, M.; Xing, M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer, 2008, 113, 2440-2447.
28. Schlumberger, M. Kinase inhibitors for refractory thyroid cancers. Lancet Oncol., 2010, 11, 912-913.
29. Collinson, F.J.; Vasudev, N.S.; Berkin, L.; Khan, M.M., Selby, P.J.; Brown, J.E. Sunitinib-induced severe hypothyroidism with cardiac compromise. Med. Oncol., 2010, DOI: 10.1007/s12032-010-9757-z.
30. Sherman, S.I. Targeted therapy of thyroid cancer. Bioch. Pharmacol., 2010, 80, 592-601.
31. Gupta-Abramson, V.; Troxel, A.B.; Nellore, A.; Puttaswamy, K.; Redlinger, M.; Ransone, K.; Mandel, S.J.; Flaherty, K.T.; Loevner, L.A.; O'Dwyer, P.J.; Brose, M.S. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol., 2008, 26, 4714-4719.
32. Kloos, R.T.; Ringel, M.D.; Knopp, M.V.; Hall, N.C.; King, M.; Stevens, R.; Liang, J.; Wakely, P.E. Jr.; Vasko V.V.; Saji, M.; Rittenberry, J.; Wei, L.; Arbogast, D.; Collamore, M.; Wright, J.J.; Grever, M.; Shah, M.H. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol., 2009, 27, 1675-1684.
33. Hoftijzer, H.; Heemstra, K.; Morreau, H.; Stokkel, M.P.; Corssmit, E.P.; Gelderblom, H.; Weijers, K.; Pereira, A.M.; Huijberts, M.; Kapiteijn, E.; Romijn, J.A.; Smit, J.W. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol., 2009, 161, 923-931.
34. Cohen, E.E.W.; Needles, B.M.; Cullen, K.J.; Wong, S.J.; Wade J.L.; Ivy, S.P.; Villaflor, V.M.; Seiwert, T.Y.; Nichols K.; Vokes E.E. In: Phase 2 study of sunitinib in refractory thyroid cancer, Proceedings of the 44° American Society of Clinical Oncology meeting, Chicago, USA, May 30 - June 3, 2008.
35. Carr, L.L.; Mankoff, D.A.; Goulart, B.H.; Eaton, K.D.; Capell, P.T.; Kell, E.M.; Bauman, J.E.; Martins, R.G. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer. Res., 2010, 16, 5260-5268.
36. Cohen, E.E.; Rosen, L.S.; Vokes, E.E.; Kies, M.S.; Forastiere, A.A.; Worden, F.P.; Kane, M.A.; Sherman, E.; Kim, S.; Bycott, P.; Tortorici, M.; Shalinsky, D.R.; Liau, K.F.; Cohen, R.B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol., 2008, 26, 4708-4713.
37. Verbeek, H.H.; Alves, M.M.; de Groot, J.W.; Osinga, J.; Plukker, J.T.; Links, T.P.; Hofstra, R.M. The Effects of Four Different Tyroisne Kinase Inhibitors on Medullary and Papillary Thyroid Cancers Cells. J. Clin. Endocrinol. Metab., 2011, doi:10.1210/jc.2010-2381.
38. Cui, J.J. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert. Opin. Ther. Pat., 2007, 17, 1035-1045.
39. de Groot, J.W.; Zonnenberg, B.A.; van Ufford-Mannesse, P.Q.; de Vries, M.M.; Links, T.P.; Lips, C.J.; Voest, E.E. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab., 2007, 92, 3466-3469.
40. Coxon, A.; Bready, J.; Estrada, J.; Osgood, T.; Canon, J.; Wang, L.; Radinsky, R.; Kendall, R.; Hughes, P.; Polverino, A. Antintumor Activity of Motesanib in a Medullary Thyroid Cancer Model. J. Endocrinol. Invest., 2011, doi:10.3275/7609.
41. Wells, S.A. Jr.; Gosnell, J.E.; Gagel, R.F.; Moley, J.; Pfister, D.; Sosa, J.A.; Skinner, M.; Krebs, A.; Vasselli, J.; Schlumberger, M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol., 2010, 28, 767-772.
42. Robinson, B.G.; Paz-Ares, L.; Krebs, A.; Vasselli, J.; Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab., 2010, 95, 2664-2671.
43. Bible, K.C.; Suman, V.J.; Molina, J.R.; Smallridge, R.C.; Maples, W.J.; Menefee, M.E.; Rubin, J.; Sideras, K.; Morris, J.C. 3rd; McIver, B.; Burton, J.K.; Webster, K.P.; Bieber, C.; Traynor, A.M.; Flynn, P.J.; Goh, B.C.; Tang, H.; Ivy, S.P.; Erlichman, C.; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Efficacy of pazopanib in pregressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol., 2010, 11, 962-972.
44. Pennell, N.A.; Daniels, G.H.; Haddad, R.I.; Ross, D.S.; Evans, T.; Wirth, L.J.; Fidias, P.H.; Temel, J.S.; Gurubhagavatula, S.; Heist, R.S.; Clark, J.R.; Lynch, T.J. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid, 2008, 18, 317-323.
45. Hoffmann, S.; Glaser, S., Wunderlich, A.; Lingelbach, S.; Dietrich, C.; Burchert, A.; Muller, H.; Rothmund, M.; Zielke, A. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks. Arch. Surg., 2006, 391, 589-596.
46. Samady, A.K.; Mukerji, R.; Shah, A.; Timmermann, B.N.; Cohen, M.S. A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo. Surgery, 2010, 148, 1228-1236.
47. Sawyers, C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell, 2002, 1, 13-15.
48. Blumenthal, R.D.; Goldenberg, D.M. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol. Biotechnol., 2007, 35, 185-197.
49. Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Berti, P.; Materazzi, G.; Minuto, M.; Giannini, R.; Marchetti, I.; Barani, L.; Basolo, F.; Ferrannini, E.; Miccoli, P. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin. Endocrinol. (Oxf), 2009, 70, 946-953.
50. Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Berti, P.; Materazzi, G.; Marchetti, I.; Ugolini, C.; Basolo, F.; Miccoli, P.; Ferrannini, E. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol., 2008, 159, 283-291.
51. Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Berti, P.; Materazzi, G.; Barani, L.; Marchetti, I.; Ferrannini, E.; Miccoli, P. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin. Endocrinol. (Oxf), 2008, 69, 148-152.
52. Antonelli, A.; Bocci, G.; La Motta, C.; Ferrari, S.M.; Fallahi, P.; Fioravanti, A.; Sartini, S.; Minuto, M.; Piaggi, S.; Corti, A.; Alì, G.; Berti, P.; Fontanini, G.; Danesi, R.; De Settimo, F.; Miccoli, P. Novel Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J. Clin. Endocrinol. Metab., 2011, 96, E288-296.
53. Schlumberger, M.J.; Elisei, R.; Bastholt, L.; Wirth, L.J.; Martins, R.G.; Locati, L.D.; Jarzab, B.; Pacini, F.; Daumerie, C.; Droz, J.P.; Eschenberg, M.J.; Sun, Y.N.; Juan, T.; Stepan, D.E.; Sherman, S.I. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol., 2009, 27, 3794-3801.
54. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8, 592-603.